Allelic loss at the D9S171 focus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma

被引:0
作者
Schraml, P
Müller, D
Bednar, R
Gasser, T
Sauter, G
Mihatsch, MJ
Moch, H
机构
[1] Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland
[2] Univ Basel, Urol Clin, CH-4003 Basel, Switzerland
关键词
papillary renal cell carcinoma; molecular genetics; chromosome; 9p; LOH; p16;
D O I
10.1002/(SICI)1096-9896(200003)190:4<457::AID-PATH551>3.0.CO;2-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Papillary renal cell carcinomas (RCCs) have characteristic clinical and morphological features that separate them from the more common clear cell RCCs, The details of the molecular changes in papillary RCC progression are not well understood. In this study, four highly polymorphic microsatellite markers [D9S970 (9p12-9p13), D9S171 (9p13), D9S1748 (9p21) and D9S156 (9p21)] were used to determine the frequency and prognostic significance of 9p deletions in 37 papillary RCCs, Allelic deletions were detected in eight cases (22%), The highest rate of loss of heterozygosity (LOH) was observed in 6 of 29 informative patients (21%) at the D9S171 locus on 9p13, Only two patients displayed allelic loss at D9S1748, which resides in close proximity to p16(INK4). TWO Of 24 informative papillary RCCs (8%) showed LOH for D9S970, LOH at D9S171 (9p13) was associated with short patient survival (p = 0.008), independently of tumour grade and stage, These data suggest a tumour suppressor gene centromeric to 9p21 that may contribute to papillary RCC progression. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:457 / 461
页数:5
相关论文
共 45 条
  • [1] Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases
    Amin, MB
    Corless, CL
    Renshaw, AA
    Tickoo, SK
    Kubus, J
    Schultz, DS
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (06) : 621 - 635
  • [2] An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO
  • [3] 2-Y
  • [4] BINGHAM CAT, 1995, P NATL ACAD SCI USA, V92, P2854
  • [5] BOSTWICK D, 1997, CANCER, V80, P973
  • [6] Bugert P, 1996, AM J PATHOL, V149, P2081
  • [7] RATES OF P16(MTS1) MUTATIONS IN PRIMARY TUMORS WITH 9P LOSS
    CAIRNS, P
    MAO, L
    MERLO, A
    LEE, DJ
    SCHWAB, D
    EBY, Y
    TOKINO, K
    VANDERRIET, P
    BLAUGRUND, JE
    SIDRANSKY, D
    [J]. SCIENCE, 1994, 265 (5170) : 415 - 416
  • [8] FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS
    CAIRNS, P
    POLASCIK, TJ
    EBY, Y
    TOKINO, K
    CALIFANO, J
    MERLO, A
    MAO, L
    HERATH, J
    JENKINS, R
    WESTRA, W
    RUTTER, JL
    BUCKLER, A
    GABRIELSON, E
    TOCKMAN, M
    CHO, KR
    HEDRICK, L
    BOVA, GS
    ISAACS, W
    KOCH, W
    SCHWAB, D
    SIDRANSKY, D
    [J]. NATURE GENETICS, 1995, 11 (02) : 210 - 212
  • [9] CAIRNS P, 1993, ONCOGENE, V8, P1083
  • [10] CAIRNS P, 1995, CANCER RES, V55, P224